Literature DB >> 23449775

'North Sea' progressive myoclonus epilepsy: phenotype of subjects with GOSR2 mutation.

Lysa Boissé Lomax1, Marta A Bayly, Helle Hjalgrim, Rikke S Møller, Annemarie M Vlaar, Kari M Aaberg, Iris Marquardt, Luke C Gandolfo, Michèl Willemsen, Erik-Jan Kamsteeg, John D O'Sullivan, G Christoph Korenke, Bastiaan R Bloem, Irenaeus F de Coo, Judith M A Verhagen, Ines Said, Trine Prescott, Asbjørg Stray-Pedersen, Magnhild Rasmussen, Danya F Vears, Anna-Elina Lehesjoki, Mark A Corbett, Melanie Bahlo, Jozef Gecz, Leanne M Dibbens, Samuel F Berkovic.   

Abstract

We previously identified a homozygous mutation in the Golgi SNAP receptor complex 2 gene (GOSR2) in six patients with progressive myoclonus epilepsy. To define the syndrome better we analysed the clinical and electrophysiological phenotype in 12 patients with GOSR2 mutations, including six new unrelated subjects. Clinical presentation was remarkably similar with early onset ataxia (average 2 years of age), followed by myoclonic seizures at the average age of 6.5 years. Patients developed multiple seizure types, including generalized tonic clonic seizures, absence seizures and drop attacks. All patients developed scoliosis by adolescence, making this an important diagnostic clue. Additional skeletal deformities were present, including pes cavus in four patients and syndactyly in two patients. All patients had elevated serum creatine kinase levels (median 734 IU) in the context of normal muscle biopsies. Electroencephalography revealed pronounced generalized spike and wave discharges with a posterior predominance and photosensitivity in all patients, with focal EEG features seen in seven patients. The disease course showed a relentless decline; patients uniformly became wheelchair bound (mean age 13 years) and four had died during their third or early fourth decade. All 12 cases had the same variant (c.430G>T, G144W) and haplotype analyses confirmed a founder effect. The cases all came from countries bounding the North Sea, extending to the coastal region of Northern Norway. 'North Sea' progressive myoclonus epilepsy has a homogeneous clinical presentation and relentless disease course allowing ready identification from the other progressive myoclonus epilepsies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449775     DOI: 10.1093/brain/awt021

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  19 in total

1.  Cortical Myoclonus in a Young Boy with GOSR2 Mutation Mimics Chorea.

Authors:  Martje E van Egmond; Anouk Kuiper; Jan Willem J Elting; Oebele F Brouwer; Tom J de Koning; Marina A J Tijssen
Journal:  Mov Disord Clin Pract       Date:  2015-02-24

2.  Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes.

Authors:  Carolina Courage; Karen L Oliver; Eon Joo Park; Jillian M Cameron; Kariona A Grabińska; Mikko Muona; Laura Canafoglia; Antonio Gambardella; Edith Said; Zaid Afawi; Betul Baykan; Christian Brandt; Carlo di Bonaventura; Hui Bein Chew; Chiara Criscuolo; Leanne M Dibbens; Barbara Castellotti; Patrizia Riguzzi; Angelo Labate; Alessandro Filla; Anna T Giallonardo; Geza Berecki; Christopher B Jackson; Tarja Joensuu; John A Damiano; Sara Kivity; Amos Korczyn; Aarno Palotie; Pasquale Striano; Davide Uccellini; Loretta Giuliano; Eva Andermann; Ingrid E Scheffer; Roberto Michelucci; Melanie Bahlo; Silvana Franceschetti; William C Sessa; Samuel F Berkovic; Anna-Elina Lehesjoki
Journal:  Am J Hum Genet       Date:  2021-04-01       Impact factor: 11.025

3.  Deep Brain Stimulation in Three Related Cases of North Sea Progressive Myoclonic Epilepsy from South Africa.

Authors:  David G Anderson; Andrea H Németh; Katherine A Fawcett; David Sims; Jack Miller; Amanda Krause
Journal:  Mov Disord Clin Pract       Date:  2016-06-16

4.  Dating rare mutations from small samples with dense marker data.

Authors:  Luke C Gandolfo; Melanie Bahlo; Terence P Speed
Journal:  Genetics       Date:  2014-05-30       Impact factor: 4.562

Review 5.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

Review 6.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

7.  A founder mutation in PET100 causes isolated complex IV deficiency in Lebanese individuals with Leigh syndrome.

Authors:  Sze Chern Lim; Katherine R Smith; David A Stroud; Alison G Compton; Elena J Tucker; Ayan Dasvarma; Luke C Gandolfo; Justine E Marum; Matthew McKenzie; Heidi L Peters; David Mowat; Peter G Procopis; Bridget Wilcken; John Christodoulou; Garry K Brown; Michael T Ryan; Melanie Bahlo; David R Thorburn
Journal:  Am J Hum Genet       Date:  2014-01-23       Impact factor: 11.025

Review 8.  Myoclonus-Ataxia Syndromes: A Diagnostic Approach.

Authors:  Malco Rossi; Sterre van der Veen; Marcelo Merello; Marina A J Tijssen; Bart van de Warrenburg
Journal:  Mov Disord Clin Pract       Date:  2020-11-03

Review 9.  Human diseases associated with form and function of the Golgi complex.

Authors:  Mariana G Bexiga; Jeremy C Simpson
Journal:  Int J Mol Sci       Date:  2013-09-10       Impact factor: 5.923

10.  Expanding the Phenotype and Genetic Defects Associated with the GOSR2 Gene.

Authors:  Roman Praschberger; Bettina Balint; Niccolo E Mencacci; Joshua Hersheson; Ignacio Rubio-Agusti; Dimitri M Kullmann; Conceição Bettencourt; Kailash Bhatia; Henry Houlden
Journal:  Mov Disord Clin Pract       Date:  2015-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.